Can neurodegenerative tissue injury release neural antigens and generate autoantibodies?

Neurodegenerative disorders involve progressive neuronal and axonal injury, which can move CNS-derived material beyond its usual compartment. The evidence supports injury-associated release of neural proteins; whether this commonly progresses to clinically meaningful, target-specific autoimmunity in human neurodegeneration is less certain.

Clinical and biomarker evidence

• Neurofilament light (NfL), an axonal structural protein, enters extracellular fluid after neuroaxonal injury. In an Alzheimer Disease Neuroimaging Initiative cohort, plasma and CSF NfL were correlated (Spearman ρ=0.59), and plasma NfL tracked cognitive decline, cerebral atrophy, and hypometabolism.
• These findings establish that neural injury is accompanied by measurable CNS-protein release into CSF and blood. However, NfL and total tau indicate neuronal injury rather than Alzheimer-specific antigen release or antigen-specific immune activation.

Autoantibodies as possible downstream signals

• Secondary autoantibody generation following neural injury is biologically plausible. Longitudinal traumatic-brain-injury data found broad early, predominantly IgM autoantibody responses, with some persisting for years.
• Persistent anti-myelin-associated glycoprotein (MAG) IgM correlated with higher NfL, consistent with an association between injury burden and autoimmunity, but not proof that antibodies cause damage—or that the same process occurs in Alzheimer disease.
• In Alzheimer disease, neural autoantibodies may be pathogenic, protective, incidental, or reflect injury; they are not broadly established as primary drivers of neurodegeneration. Proposed markers including myelin basic protein, tubulin, dopamine- or serotonin-related targets, GFAP IgM, and amphiphysin lack validation as Alzheimer-specific injury markers.

Mechanistic context

• Blood–brain barrier dysfunction and altered CNS-to-lymphatic drainage could permit released neural material to encounter peripheral immune compartments.
• Experimental peripheral exposure to spinal-cord homogenate increased CNS-reactive antibodies, inflammatory cytokines, and neural degeneration in rats, supporting the underlying immune-exposure mechanism.

Bottom line

• Neural injury-associated antigen release is supported; secondary autoantibodies are a credible downstream consequence and potential marker of damage, but their target-specific clinical meaning and causal role in neurodegenerative disease remain unresolved.